Current constitutional documents

Click here

Most recent admission document

Click here

Details of Any Other Exchanges or Trading Platforms

The company is not quoted on any other exchanges or trading platforms

Details of any Restrictions on the Transfer of Securities

There are no restrictions on the transfer of Abingdon Health securities

Whether the Company is subject to the UK City Code on Takeovers and Mergers

The company is subject to the UK City Code on Takeovers and Mergers

Country of Incorporation and Main Country of Operation

Abingdon Health was incorporated in England and Wales on 16 January 2008 (Registration No. 06475379) and is headquartered in York, UK, with an additional site in Doncaster.

Number of Securities in Issue

Issued share capital consists of 121,716,822 ordinary shares of 0.025p each.

AIM securities not in public hands

In so far as the Company is aware, the percentage of AIM securities not in public hands is: 32.48%.

Significant Shareholders (3% or over)

Shareholder Ordinary Shares Issued Share Capital (%)
Enterprise Ventures (General Partner NPIF YHTV Equity) Ltd 18,071,164 14.85%
Chris Hand 13,178,467 10.83%
Hargreaves Lansdown Asset Mgt 10,279,031 8.45%
Chris Yates 7,888,844 6.48%
Catenalucis LLC 7,088,488 5.82%
Interactive Investor 7,024,040 5.77%
Thornapple LLP 6,113,124 5.02%
Jarvis Investment Management 4,488,220 3.69%
Touchstone Innovations Businesses LLP 4,164,756 3.42%

This information was last updated on 16th January 2024.

Description of business

Click here

Board and Governance

Click here

Documents and Reports

Click here

Regulatory Announcements

Click here

Advisors

Nominated Advisor and Broker:
Singer Capital Markets
One Bartholomew Lane
London EC2N 2AX

Solicitors to the Company:
Squire Patton Boggs (UK) LLP
6 Wellington Place
Leeds LS1 4AP

Reporting Accountant and Auditor:
BDO LLP
Central Square
29 Wellington Street
Leeds LS1 4DL

Registrar:
Link Group
The Registry
34 Beckenham Road
Beckenham
Kent BR3 4TU

Financial Press Office:
For all investor relations enquiries, please contact [email protected].